- Company
- Opdivo retries expanding reimbursement without NSCLC
- by Eo, Yun-Ho Feb 6, 2020 06:31am
- Seemingly have given up on expanding reimbursement, Opdivo has turned around and started taking actions again. Nevertheless, its health coverage application excluded indication for lung cancer. According to industry sources, Ono Pharmaceutical and BMS have recently applied for expanding reimbursement on PD-1 inhibitor-based immunotherapy
- Company
- Pelubi’s indication expansion, seeking for breakthrough
- by Kim, Jin-Gu Feb 6, 2020 06:30am
- Daewon Pharm challenges the expansion of Pelubi's patented indication. Pelubi's indication for osteoarthritis is extended to dysmenorrhea. Recently, Pelubi CR’s phase III trial plan by Daewon was approved from the Ministry of Food and Drug Safety. This is a phase III clinical trial in Korea to evaluate the efficacy and safety of DW9801
- Company
- Pharmaceuticals are focusing on domestic actions for NDMA
- by Chon, Seung-Hyun Feb 6, 2020 06:30am
- Investigations have shown that Metformin's impurity content is safe in the US and EU. In Korea, the Ministry of Food and Drug Safety has also begun inspections after deriving the test method. The US Food and Drug Administration (FDA) announced on the website that some of the Metformin products sold under the FDA approval and carcinogenic subs
- Company
- HIV drug as alternative treatment for new coronavirus?
- by Nho, Byung Chul Feb 6, 2020 06:30am
- In the midst of the novel coronavirus outbreak, a few countries are using HIV medication as an alternative treatment. 48 hours after receiving HIV drug, a confirmed patient with initial symptoms in China and a 40-year-old female patient in Thailand have been tested negative for the novel coronavirus. In Korea, the 14th patient has been r
- Company
- Global companies work from home due to outbreak
- by Kim, Jin-Gu Feb 6, 2020 06:29am
- Impact of the novel coronavirus is spreading through the Korean pharmaceutical industry. Currently, at least nine pharmaceutical companies have been confirmed to work from home and the number is increasing. The industry reported on Feb. 3, Pfizer Korea, Novartis Korea, MSD Korea, AstraZeneca Korea, Bristol-Myers Squibb Korea, Sanofi-
- Company
- Boryeong Holdings establishes a US subsidiary
- by An, Kyung-Jin Feb 6, 2020 06:29am
- Boryeong Holdings announced on January 22 that it established a local corporation in San Francisco, USA and officially started business. The local corporation name is ‘HAYAN HEALTH NETWORKS’, and Sung-won Choi, currently the executive director of the global business headquarters of Boryung Pharmaceutical, will be the first director. Bory
- Company
- Targeted therapy and immunotherapy as new TNBC options
- by Eo, Yun-Ho Feb 5, 2020 05:59am
- Sources say one of highly unmet medical need, triple negative breast cancer, now has two more treatment options. The pharmaceutical industry reported on Feb. 5 that AstraZeneca’s targeted therapy Lynparza (olaparib) and Roche’s immunotherapy Tecentriq (atezolizumab) respectively received new indication in last October and January, to
- Company
- Lazertinib by Yuhan launches global phase III clinical trial
- by An, Kyung-Jin Feb 5, 2020 05:59am
- Global Phase III clinical trial of anticancer drug candidate 'Lazertinib' by Yuhan is in full swing. On the 3rd, Yuhan Corporation announced that it will hold an initiation meeting for each institution after receiving the Lazertinib phase III clinical trial approval (IND) from the MFDS in December last year, and will soon begin recrui
- Company
- Last to join HCV treatment game Mavyret tops in 1 year
- by Kim, Jin-Gu Feb 5, 2020 05:59am
- Taking up 81 percent of the market share, Mavyret has been prominently leading the hepatitis C treatment market making 40.3 billion won last year. However, the prescription volume fell for two consecutive quarters due to reduced number of patients. Pharmaceutical market research firm UBIST on Feb. 3 said eight of direct-acting antiviral
- Company
- Heated argument over Botulinum lawsuit in USA is expected
- by Kim, Jin-Gu Feb 5, 2020 05:58am
- A trial of the controversial botulinum toxin strain between Medytox and Daewoong Pharmaceutical began in the United States. According to the pharmaceutical industry, the US International Trade Commission (ITC) entered a trial on the 4th of the case against Daewoong Pharmaceutical and Medytox. The trial lasts four days until the 7th. The
